Not rendering correctly? View this email as a web page here.
header2-4.jpg
Forward  arrow
newsletter 23.6.19

Big news this past week as Zebra Medical Vision received FDA clearance for its AI-powered intracranial hemorrhage detection product, its second FDA approval in a month! Congrats to sugar reduction company DouxMatok on their $22M raise; OurCrowd is proud to take part in this effort to reduce the world's sugar dependency. data.world is bringing data to the next level with its recent acquisition of Capsenta - read about it here, and find more top news below.

Startup Nation and beyond 

New in medical cannabis: Syqe Medical releases its first cannabis inhaler.

The latest on Intel and Israel: The reality of autonomous cars is beginning to feel closer as Intel's Mobileye plans to launch a trial of robo-cabs next year in Israel. Intel has also announced its accelerator launch in Israel, which aims to give early-stage startups "a unique advantage in their quest to disrupt the future."

Sweetch on the front lines of disease prevention: Getting healthy with tech.

Top tech news this week 

News from the industry 

From cars, to pacemakers, to ATMs, our networked world is becoming more and more vulnerable to cyber attacks. Read up on Cybersecurity in a Connected World (OurCrowd)

Andy Kessler on The Future Isn’t What It Used to Be (The Wall Street Journal)

By Alec Ellison, OurCrowd's Chairman of US Operations, and Steven Gray: Where AI Creates Winners – and Losers (Techonomy)

The latest from OurCrowd 

Outsmart the weather with forecasts that provide minute-by-minute and street-by-street level accuracy. ClimaCell’s recently-launched app is currently available for iOS users in the US and UK for free, along with some great premium features you can check out. Help us help them by downloading it from here, rating, and commenting on the app!

This past week we hosted an exclusive gathering for our Israeli investor community in the first of the OurCrowd TLV Series. We heard venture insights on the latest in cyber technology and got a first-look at investment opportunities in an intimate setting with good food, drinks, and networking - looking forward to more to come!

See which OurCrowd events are taking place near you on our Events Calendar.

Looking to connect

OurCrowd is seeking introductions to senior executives at pharmaceutical companies. If you can make a relevant introduction, please click the button below:

Get Involved 

We currently have 500+ open positions at our global portfolio companies. Here are a few of the most exciting:

Search and filter through OurTalent to find your next challenge.
Jon-Medved-Profile-(4-of-6).png

See you next week,

Jon Medved
CEO
OurCrowd

Follow me on Facebook, Twitter and LinkedIn 


Forwarded by a friend? Subscribe to the newsletter

Follow us:
social_A-1
social_A-1
social_B-1
social_C-1
You received this email because you are subscribed to emails from OurCrowd.
Update your email preferences to choose the types of emails you receive.

Nothing contained in and accompanying this communication shall be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security by OurCrowd, its portfolio companies or any third party. Information regarding OurCrowd’s limited partnerships and/or portfolio companies and the investment opportunities  on OurCrowd’s website is intended and available for accredited investors only (criteria at OurCrowd). OurCrowd urges potential investors to consult with licensed legal professionals and investment advisors for any legal, tax, insurance, or investment advice. UK & Europe only - OurCrowd Management (UK) Limited is an Appointed Representative of Met Facilities LLP which is authorized and regulated by the Financial Conduct Authority (reference number 587084). OurCrowd Management (UK) Limited is registered in England (registration number 10522689). OurCrowd operates in Canada through OurCrowd Canada Inc., an exempt market dealer registered in the Provinces of Ontario, British Colombia, Alberta, Manitoba, Quebec and Nova Scotia.